REGENXBIO Competitors

REGENXBIO (NASDAQ:RGNX) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Earnings and Valuation

This table compares REGENXBIO and Adaptive Biotechnologies' gross revenue, earnings per share (EPS) and valuation.

Adaptive Biotechnologies has higher revenue and earnings than REGENXBIO. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

75.2% of REGENXBIO shares are held by institutional investors. Comparatively, 80.8% of Adaptive Biotechnologies shares are held by institutional investors. 14.1% of REGENXBIO shares are held by insiders. Comparatively, 22.2% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares REGENXBIO and Adaptive Biotechnologies' net margins, return on equity and return on assets.

Risk and Volatility

REGENXBIO has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for REGENXBIO and Adaptive Biotechnologies, as reported by MarketBeat.com.

REGENXBIO presently has a consensus price target of $62.50, suggesting a potential upside of 81.79%. Adaptive Biotechnologies has a consensus price target of $61.40, suggesting a potential upside of 46.71%. Given REGENXBIO's stronger consensus rating and higher probable upside, analysts clearly believe REGENXBIO is more favorable than Adaptive Biotechnologies.

Summary

Adaptive Biotechnologies beats REGENXBIO on 8 of the 15 factors compared between the two stocks.

REGENXBIO (NASDAQ:RGNX) and China Biologic Products (NASDAQ:CBPO) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Risk and Volatility

REGENXBIO has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, China Biologic Products has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500.

Earnings and Valuation

This table compares REGENXBIO and China Biologic Products' gross revenue, earnings per share (EPS) and valuation.

China Biologic Products has higher revenue and earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than China Biologic Products, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares REGENXBIO and China Biologic Products' net margins, return on equity and return on assets.

Insider & Institutional Ownership

75.2% of REGENXBIO shares are held by institutional investors. Comparatively, 34.8% of China Biologic Products shares are held by institutional investors. 14.1% of REGENXBIO shares are held by insiders. Comparatively, 2.7% of China Biologic Products shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for REGENXBIO and China Biologic Products, as reported by MarketBeat.com.

REGENXBIO presently has a consensus price target of $62.50, suggesting a potential upside of 81.79%. Given REGENXBIO's higher probable upside, analysts clearly believe REGENXBIO is more favorable than China Biologic Products.

REGENXBIO (NASDAQ:RGNX) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk.

Risk and Volatility

REGENXBIO has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500.

Valuation and Earnings

This table compares REGENXBIO and Allogene Therapeutics' gross revenue, earnings per share and valuation.

REGENXBIO has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares REGENXBIO and Allogene Therapeutics' net margins, return on equity and return on assets.

Institutional & Insider Ownership

75.2% of REGENXBIO shares are held by institutional investors. Comparatively, 59.9% of Allogene Therapeutics shares are held by institutional investors. 14.1% of REGENXBIO shares are held by insiders. Comparatively, 31.3% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for REGENXBIO and Allogene Therapeutics, as reported by MarketBeat.com.

REGENXBIO currently has a consensus price target of $62.50, suggesting a potential upside of 81.79%. Allogene Therapeutics has a consensus price target of $52.0833, suggesting a potential upside of 60.55%. Given REGENXBIO's stronger consensus rating and higher probable upside, equities research analysts clearly believe REGENXBIO is more favorable than Allogene Therapeutics.

Summary

REGENXBIO beats Allogene Therapeutics on 9 of the 13 factors compared between the two stocks.

REGENXBIO (NASDAQ:RGNX) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk.

Institutional & Insider Ownership

75.2% of REGENXBIO shares are held by institutional investors. Comparatively, 49.8% of Beam Therapeutics shares are held by institutional investors. 14.1% of REGENXBIO shares are held by insiders. Comparatively, 0.7% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for REGENXBIO and Beam Therapeutics, as reported by MarketBeat.com.

REGENXBIO currently has a consensus price target of $62.50, suggesting a potential upside of 81.79%. Beam Therapeutics has a consensus price target of $96.00, suggesting a potential upside of 31.18%. Given REGENXBIO's stronger consensus rating and higher probable upside, equities research analysts clearly believe REGENXBIO is more favorable than Beam Therapeutics.

Valuation and Earnings

This table compares REGENXBIO and Beam Therapeutics' gross revenue, earnings per share and valuation.

Beam Therapeutics has lower revenue, but higher earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares REGENXBIO and Beam Therapeutics' net margins, return on equity and return on assets.

Summary

REGENXBIO beats Beam Therapeutics on 11 of the 14 factors compared between the two stocks.

Iovance Biotherapeutics (NASDAQ:IOVA) and REGENXBIO (NASDAQ:RGNX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk and dividends.

Valuation & Earnings

This table compares Iovance Biotherapeutics and REGENXBIO's gross revenue, earnings per share and valuation.

REGENXBIO has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Iovance Biotherapeutics and REGENXBIO, as reported by MarketBeat.

Iovance Biotherapeutics currently has a consensus price target of $50.50, suggesting a potential upside of 64.87%. REGENXBIO has a consensus price target of $62.50, suggesting a potential upside of 81.79%. Given REGENXBIO's higher probable upside, analysts plainly believe REGENXBIO is more favorable than Iovance Biotherapeutics.

Volatility and Risk

Iovance Biotherapeutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500.

Institutional and Insider Ownership

94.6% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 75.2% of REGENXBIO shares are owned by institutional investors. 9.9% of Iovance Biotherapeutics shares are owned by company insiders. Comparatively, 14.1% of REGENXBIO shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Iovance Biotherapeutics and REGENXBIO's net margins, return on equity and return on assets.

Summary

REGENXBIO beats Iovance Biotherapeutics on 9 of the 14 factors compared between the two stocks.

REGENXBIO (NASDAQ:RGNX) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Valuation & Earnings

This table compares REGENXBIO and SpringWorks Therapeutics' revenue, earnings per share (EPS) and valuation.

SpringWorks Therapeutics has lower revenue, but higher earnings than REGENXBIO. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for REGENXBIO and SpringWorks Therapeutics, as provided by MarketBeat.

REGENXBIO presently has a consensus target price of $62.50, suggesting a potential upside of 81.79%. SpringWorks Therapeutics has a consensus target price of $95.20, suggesting a potential upside of 33.26%. Given REGENXBIO's higher probable upside, research analysts clearly believe REGENXBIO is more favorable than SpringWorks Therapeutics.

Risk and Volatility

REGENXBIO has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.

Insider and Institutional Ownership

75.2% of REGENXBIO shares are owned by institutional investors. Comparatively, 76.3% of SpringWorks Therapeutics shares are owned by institutional investors. 14.1% of REGENXBIO shares are owned by insiders. Comparatively, 51.2% of SpringWorks Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares REGENXBIO and SpringWorks Therapeutics' net margins, return on equity and return on assets.

Summary

REGENXBIO beats SpringWorks Therapeutics on 9 of the 14 factors compared between the two stocks.